ArticleCureus2025
Immunohistochemical Expression of Vitamin D Receptors (VDRs) and Estrogen Receptor Beta 1 (ERβ1) in Molecular Subtypes of Triple-Negative Breast Cancer Tumors: A Cross-Sectional Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Albumin-bound paclitaxel drives a cytotoxic CD8Frontiers in immunology · 2026Article
- Targeting ERβ1-Positive Triple-Negative Breast Cancer: Molecular Effects of Calcitriol and 17β-Estradiol.Cureus · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Breast cancer (BC) is still the most common malignancy among women globally, and triple-negative breast cancer (TNBC) presents major therapeutic and management issues due to its aggressive nature. Recent studies suggest that the vitamin D receptor (VDR) and estrogen receptor beta 1 (ERβ1) play crucial roles in regulating TNBC progression. Increased expression of VDR and ERβ1 has been linked to tumor suppression, highlighting their potential to impact cancer progression via various signaling pathways. This study analyzes VDR and ERβ1 expressions in TNBC subtypes to discover potential therapeutic targets and improve treatment outcomes for this challenging BC subtype. Method This cross-sectional study analyzed 30 invasive ductal carcinoma (IDC) cases of TNBC subtypes using formalin-fixed paraffin embedding (FFPE) tissues. Immunohistochemistry assessed cytoplasmic and nuclear VDR and ERβ1 expression, scoring staining intensity and extent, categorized as negative/low, moderate, or high expression. Results High VDR and ERβ1 expressions were analyzed across molecular subtypes of TNBC to explore their therapeutic potential, particularly in TNBC. In TNBC, a high VDR expression was observed in the cytoplasm (n = 10, 33.3%) and the nucleus (n = 2, 6.6%), with statistical significance (p < 0.042). Luminal A cases demonstrated high VDR expression in the cytoplasm (n = 6, 20%) and the nucleus (n = 2, 6.6%) (p < 0.042), while luminal B exhibited high VDR expression exclusively in the cytoplasm (n = 4, 13.3%) (p < 0.042). In HER2-enriched, high VDR expression was confined to the nucleus (n = 3, 10%) (p < 0.042). ERβ1 expression patterns in TNBC showed moderate cytoplasmic expression (n = 9, 50%) and high cytoplasmic expression (n = 1, 5.5%), with statistical significance (p < 0.025). By contrast, luminal A displayed moderate cytoplasmic expression (n = 3, 16.6%) and high cytoplasmic expression (n = 5, 27.7%) (p < 0.025). These findings suggest that VDR and ERβ1 exhibit subtype-specific expression patterns, with significant expression in TNBC, indicating their potential as therapeutic targets. Conclusion VDR and ERβ1 expressions differ between TNBC subtypes, indicating their potential as targeted therapies, particularly in TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.